Sanjay Nayak

OCUL

CHIEF STRATEGY OFFICER · OCULAR THERAPEUTIX, INC · CIK 0002012715

FILING MIX · LIFETIME38%/62%

BUYS

SELLS

TOTAL VALUE

$241.1K

COMPANIES

ACTIVE SINCE

Feb 2024

HOLDINGS NOW

328,795

AVG SELL PX

$8.80

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

9 backtested trades · 8 horizons · 14 pendingHow are these numbers computed? →

Forward-return performance of every backtestable P/S trade by Sanjay Nayak, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.

HORIZON	TRADES	WIN RATE	INSIDER RETURN	SPY RETURN	MEAN EXCESS	MEDIAN EXCESS	T-STAT
7d	9	+44.44%	+1.57%	+0.29%	+1.28%	+0.64%	—
14d	9	+22.22%	+9.59%	+0.01%	+9.57%	+6.09%	—
30d	9	+44.44%	+3.07%	+0.58%	+2.49%	+2.80%	—
60d	9	+44.44%	+12.50%	+2.98%	+9.52%	+8.22%	—
90d	9	+44.44%	+8.07%	+4.41%	+4.95%	-4.56%	—
180d	9(2 pending)	+57.14%	+13.69%	+8.39%	+13.19%	+11.81%	—
1y	9(4 pending)	+0.00%	+27.52%	+16.94%	+10.57%	+17.82%	—
2y	9(8 pending)	+0.00%	+38.45%	+42.93%	-4.48%	-4.48%	—

How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.

Holdings over time

OCUL · 328,795 shares · as of May 26, 2026

Trading cadence · quarterly flow

BUY ● SELL ●

2024

2025

2026

FLOW · 6 buys / 10 sellsCOVERAGE · 10 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED	DETAILS
OCUL OCULAR THERAPEUTIX, INC	SALE10b5-1 10b5-1 plan	1,858	$8.20	$15.2K	328,795	May 26, 2026	May 28, 2026 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	SALE10b5-1 10b5-1 plan	1,759	$8.28	$14.6K	330,653	Feb 23, 2026	Feb 25, 2026 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	SALE10b5-1 10b5-1 plan	10,348	$9.04	$93.5K	332,412	Feb 12, 2026	Feb 17, 2026 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	PURCHASEGRANT Stock grant	64,900	—	—	342,760	Jan 2, 2026	Jan 6, 2026 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	PURCHASEGRANT Stock grant	197,650	—	—	197,650	Jan 2, 2026	Jan 6, 2026 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	SALE10b5-1 10b5-1 plan	1,878	$12.04	$22.6K	277,860	Nov 24, 2025	Nov 26, 2025 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	SALE10b5-1 10b5-1 plan	1,885	$12.04	$22.7K	279,738	Aug 25, 2025	Aug 27, 2025 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	SALE10b5-1 10b5-1 plan	1,862	$7.17	$13.4K	281,623	May 23, 2025	May 27, 2025 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	SALE10b5-1 10b5-1 plan	1,895	$6.84	$13.0K	283,485	Feb 24, 2025	Feb 26, 2025 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	PURCHASEGRANT Stock grant	334,000	—	—	334,000	Feb 11, 2025	Feb 13, 2025 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	PURCHASEGRANT Stock grant	111,000	—	—	285,380	Feb 11, 2025	Feb 13, 2025 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	SALE10b5-1 10b5-1 plan	1,814	$9.00	$16.3K	174,380	Nov 25, 2024	Nov 27, 2024 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	SALE10b5-1 10b5-1 plan	1,832	$9.02	$16.5K	176,194	Aug 23, 2024	Aug 27, 2024 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	SALE10b5-1 10b5-1 plan	2,274	$5.84	$13.3K	178,026	May 23, 2024	May 28, 2024 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	PURCHASEGRANT Stock grant	80,300	—	—	180,300	Feb 22, 2024	Feb 26, 2024 ↗	View →
OCUL OCULAR THERAPEUTIX, INC	PURCHASEGRANT Stock grant	244,550	—	—	244,550	Feb 22, 2024	Feb 26, 2024 ↗	View →

Other insiders · OCUL

Loading peer insiders…

About this filer

CIK 0002012715

ROLE

Chief Strategy Officer

PRIMARY

OCUL

COMPANIES

ACTIVE SINCE

Feb 2024

MARKETPEEL · /INSIDER/0002012715DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

Sanjay Nayak

The morning brief, before the bell.